SEC Form 3 · accession 0001209191-16-151980
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Nov 23, 2016
Accepted (ET)
Nov 23, 2016 · 4:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 7,552,084 | I | 0 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Held by Nestle Health Science US Holdings, Inc. Nestle Health Science US Holdings, Inc. is wholly owned subsidiary of NIMCO US, Inc., which is a wholly owned subsidiary of Nestle S.A., a publicly traded company. Each of these entities may be deemed to share voting and investment power with respect to all shares held by Nestle Health Science US Holdings, Inc. Each of the filing persons disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.